<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542046</url>
  </required_header>
  <id_info>
    <org_study_id>15-16964</org_study_id>
    <nct_id>NCT02542046</nct_id>
  </id_info>
  <brief_title>Uniformity of Oral Contrast Material in the Bowel</brief_title>
  <official_title>Uniformity of Oral Contrast Material in the Bowel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although positive oral contrast agents are used for the majority of abdominopelvic CT scans
      in the United States, the quality of bowel opacification has not been compared between the
      three major classes of positive oral contrast material (barium sulfate, ionic iodinated
      contrast material, and non-ionic iodinate contrast material). This is a retrospective single
      institution study of clinical records to show whether the uniformity of bowel opacification
      is different between the three main types of positive CT oral contrast material used in the
      United States (Barium sulfate, Diatrizoate, and Iohexol). The investigators will
      retrospectively identify 250 patients each who received oral barium sulfate, diatrizoate, and
      iohexol for CT scanning of the abdomen and pelvis (total 750 patients) and assess the quality
      of bowel lumen opacification by the positive oral contrast agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although positive oral contrast agents are used for the majority of abdominopelvic CT scans
      in the United States, the quality of bowel opacification has not been compared between the
      three major classes of positive oral contrast material (barium sulfate, ionic iodinated
      contrast material, and non-ionic iodinate contrast material). The investigators will
      retrospectively identify 250 patients each who received oral barium sulfate, diatrizoate, and
      iohexol for CT scanning of the abdomen and pelvis (total 750 patients) and assess the quality
      of bowel lumen opacification by the positive oral contrast agents.

      Primary objective:

        -  To show the uniformity of bowel opacification is different between the three main types
           of CT oral contrast material used in the United States (Barium sulfate, Diatrizoate, and
           Iohexol).

      Secondary objectives:

        -  To show whether or not one of the oral contrast agents provides more uniform
           opacification than the others in the proximal or distal bowel

        -  To assess the relative opacification of the distal small bowel (ileum) by the three
           contrast agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Non-uniform Bowel Lumen Opacification at CT Imaging</measure>
    <time_frame>within 1 day from administration of oral contrast. The CT scan generally occurs within 3 hours after oral contrast administration, and the CT scan images will be evaluated for the imaging appearance of oral contrast uniformity for this outcome.</time_frame>
    <description>Nonuniform contrast enhancement of the bowel lumen is a potential diagnostic pitfall at CT imaging since non-uniform enhancement may be distracting to the reader and interfere with accurate diagnosis. Conversely, homogeneously enhancing bowel lumen makes it easier to assess the bowel for potential disease. For each patient's CT scan, the bowel that is seen to be visibly opacified by oral contrast at CT imaging will be assessed as a whole as showing the presence or absence of nonuniform contrast enhancement of the lumen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of CT Imaging Artifacts Caused by the Oral Contrast Agent</measure>
    <time_frame>within 1 day from administration of oral contrast. The CT scan generally occurs within 3 hours after oral contrast administration, and the CT scan images will be evaluated for the imaging appearance of oral contrast uniformity for this outcome.</time_frame>
    <description>For the segments of bowel visibly opacified by oral contrast, the severity of CT imaging artifacts caused by the oral contrast agent was recorded on the following 3 point scale: 0 = no artifact; 1 = mild artifact without impairment of anatomic delineation; 2 = severe artifact with impairment of anatomic delineation. Lower scores are preferred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of Bowel Opacification of Bowel at CT Imaging</measure>
    <time_frame>within 1 day from administration of oral contrast. The CT scan generally occurs within 3 hours after oral contrast administration, and the CT scan images will be evaluated for imaging appearance of oral contrast seen in bowel for this outcome.</time_frame>
    <description>The most distal segment of bowel (stomach, jejunum, ileum, and /or colon) that was opacified by contrast material at the time of CT imaging was recorded</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">900</enrollment>
  <condition>Known or Suspected Abdominal Disease</condition>
  <arm_group>
    <arm_group_label>Barium</arm_group_label>
    <description>Patients who received barium sulfate oral contrast for abdominopelvic CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diatrizoate</arm_group_label>
    <description>Patients who received diatrizoate oral contrast for abdominopelvic CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iohexol</arm_group_label>
    <description>Patients who received iohexol oral contrast for abdominopelvic CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Barium</intervention_name>
    <description>Administration of barium oral contrast agent prior to CT scan</description>
    <arm_group_label>Barium</arm_group_label>
    <other_name>Barium sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diatrizoate</intervention_name>
    <description>Administration of diatrizoate oral contrast agent prior to CT scan</description>
    <arm_group_label>diatrizoate</arm_group_label>
    <other_name>ionic iodinated contrast agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Administration of iohexol oral contrast agent prior to CT scan</description>
    <arm_group_label>iohexol</arm_group_label>
    <other_name>nonionic iodinated contrast agent</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients in our institution who had undergone CT of the Abdomen and Pelvis with
        administration of positive oral contrast material
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CT scans in which oral contrast material was given

        Exclusion Criteria:

          -  CT scans in which an obvious paucity of oral contrast material is seen,

          -  CT scans of patients who had studies within 1 week prior where enteric contrast may
             have been given, including fluoroscopic, endoscopic, or interventional studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Yeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Doyle GJ, O'Donnell SC, McDonald JR, Murthy LN, Keir MJ, Wright AR. Evaluation of &quot;Gastromiro&quot; for bowel opacification during computed tomography: comparison with diatrizoate and barium sulphate. Br J Radiol. 1993 Aug;66(788):681-4.</citation>
    <PMID>7719680</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <results_first_submitted>March 25, 2019</results_first_submitted>
  <results_first_submitted_qc>November 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2019</results_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Benjamin M. Yeh, MD</investigator_full_name>
    <investigator_title>Professor of Radiology. Principal Investigator</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Barium</title>
          <description>Patients who received barium sulfate oral contrast for abdominopelvic CT
Barium: Administration of barium oral contrast agent prior to CT scan</description>
        </group>
        <group group_id="P2">
          <title>Diatrizoate</title>
          <description>Patients who received diatrizoate oral contrast for abdominopelvic CT
Diatrizoate: Administration of diatrizoate oral contrast agent prior to CT scan</description>
        </group>
        <group group_id="P3">
          <title>Iohexol</title>
          <description>Patients who received iohexol oral contrast for abdominopelvic CT
Iohexol: Administration of iohexol oral contrast agent prior to CT scan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Barium</title>
          <description>Patients who received barium sulfate oral contrast for abdominopelvic CT
Barium: Administration of barium oral contrast agent prior to CT scan</description>
        </group>
        <group group_id="B2">
          <title>Diatrizoate</title>
          <description>Patients who received diatrizoate oral contrast for abdominopelvic CT
Diatrizoate: Administration of diatrizoate oral contrast agent prior to CT scan</description>
        </group>
        <group group_id="B3">
          <title>Iohexol</title>
          <description>Patients who received iohexol oral contrast for abdominopelvic CT
Iohexol: Administration of iohexol oral contrast agent prior to CT scan</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="300"/>
            <count group_id="B3" value="300"/>
            <count group_id="B4" value="900"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="300"/>
                    <count group_id="B4" value="900"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" lower_limit="22" upper_limit="86"/>
                    <measurement group_id="B2" value="58.9" lower_limit="22" upper_limit="91"/>
                    <measurement group_id="B3" value="58.9" lower_limit="21" upper_limit="90"/>
                    <measurement group_id="B4" value="58.5" lower_limit="21" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="300"/>
                    <count group_id="B3" value="300"/>
                    <count group_id="B4" value="900"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="186"/>
                    <measurement group_id="B4" value="550"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non-uniform Bowel Lumen Opacification at CT Imaging</title>
        <description>Nonuniform contrast enhancement of the bowel lumen is a potential diagnostic pitfall at CT imaging since non-uniform enhancement may be distracting to the reader and interfere with accurate diagnosis. Conversely, homogeneously enhancing bowel lumen makes it easier to assess the bowel for potential disease. For each patient's CT scan, the bowel that is seen to be visibly opacified by oral contrast at CT imaging will be assessed as a whole as showing the presence or absence of nonuniform contrast enhancement of the lumen.</description>
        <time_frame>within 1 day from administration of oral contrast. The CT scan generally occurs within 3 hours after oral contrast administration, and the CT scan images will be evaluated for the imaging appearance of oral contrast uniformity for this outcome.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Barium</title>
            <description>Patients who received barium sulfate oral contrast for abdominopelvic CT
Barium: Administration of barium oral contrast agent prior to CT scan</description>
          </group>
          <group group_id="O2">
            <title>Diatrizoate</title>
            <description>Patients who received diatrizoate oral contrast for abdominopelvic CT
Diatrizoate: Administration of diatrizoate oral contrast agent prior to CT scan</description>
          </group>
          <group group_id="O3">
            <title>Iohexol</title>
            <description>Patients who received iohexol oral contrast for abdominopelvic CT
Iohexol: Administration of iohexol oral contrast agent prior to CT scan</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-uniform Bowel Lumen Opacification at CT Imaging</title>
          <description>Nonuniform contrast enhancement of the bowel lumen is a potential diagnostic pitfall at CT imaging since non-uniform enhancement may be distracting to the reader and interfere with accurate diagnosis. Conversely, homogeneously enhancing bowel lumen makes it easier to assess the bowel for potential disease. For each patient's CT scan, the bowel that is seen to be visibly opacified by oral contrast at CT imaging will be assessed as a whole as showing the presence or absence of nonuniform contrast enhancement of the lumen.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severity of CT Imaging Artifacts Caused by the Oral Contrast Agent</title>
        <description>For the segments of bowel visibly opacified by oral contrast, the severity of CT imaging artifacts caused by the oral contrast agent was recorded on the following 3 point scale: 0 = no artifact; 1 = mild artifact without impairment of anatomic delineation; 2 = severe artifact with impairment of anatomic delineation. Lower scores are preferred</description>
        <time_frame>within 1 day from administration of oral contrast. The CT scan generally occurs within 3 hours after oral contrast administration, and the CT scan images will be evaluated for the imaging appearance of oral contrast uniformity for this outcome.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Barium</title>
            <description>Patients who received barium sulfate oral contrast for abdominopelvic CT
Barium: Administration of barium oral contrast agent prior to CT scan</description>
          </group>
          <group group_id="O2">
            <title>Diatrizoate</title>
            <description>Patients who received diatrizoate oral contrast for abdominopelvic CT
Diatrizoate: Administration of diatrizoate oral contrast agent prior to CT scan</description>
          </group>
          <group group_id="O3">
            <title>Iohexol</title>
            <description>Patients who received iohexol oral contrast for abdominopelvic CT
Iohexol: Administration of iohexol oral contrast agent prior to CT scan</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of CT Imaging Artifacts Caused by the Oral Contrast Agent</title>
          <description>For the segments of bowel visibly opacified by oral contrast, the severity of CT imaging artifacts caused by the oral contrast agent was recorded on the following 3 point scale: 0 = no artifact; 1 = mild artifact without impairment of anatomic delineation; 2 = severe artifact with impairment of anatomic delineation. Lower scores are preferred</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No artifact</title>
                  <measurement_list>
                    <measurement group_id="O1" value="296"/>
                    <measurement group_id="O2" value="294"/>
                    <measurement group_id="O3" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild artifact</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe artifact</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extent of Bowel Opacification of Bowel at CT Imaging</title>
        <description>The most distal segment of bowel (stomach, jejunum, ileum, and /or colon) that was opacified by contrast material at the time of CT imaging was recorded</description>
        <time_frame>within 1 day from administration of oral contrast. The CT scan generally occurs within 3 hours after oral contrast administration, and the CT scan images will be evaluated for imaging appearance of oral contrast seen in bowel for this outcome.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Barium</title>
            <description>Patients who received barium sulfate oral contrast for abdominopelvic CT
Barium: Administration of barium oral contrast agent prior to CT scan</description>
          </group>
          <group group_id="O2">
            <title>Diatrizoate</title>
            <description>Patients who received diatrizoate oral contrast for abdominopelvic CT
Diatrizoate: Administration of diatrizoate oral contrast agent prior to CT scan</description>
          </group>
          <group group_id="O3">
            <title>Iohexol</title>
            <description>Patients who received iohexol oral contrast for abdominopelvic CT
Iohexol: Administration of iohexol oral contrast agent prior to CT scan</description>
          </group>
        </group_list>
        <measure>
          <title>Extent of Bowel Opacification of Bowel at CT Imaging</title>
          <description>The most distal segment of bowel (stomach, jejunum, ileum, and /or colon) that was opacified by contrast material at the time of CT imaging was recorded</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stomach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duodenum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jejunum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ileum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="174"/>
                    <measurement group_id="O3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Barium</title>
          <description>Patients who received barium sulfate oral contrast for abdominopelvic CT
Barium: Administration of barium oral contrast agent prior to CT scan</description>
        </group>
        <group group_id="E2">
          <title>Diatrizoate</title>
          <description>Patients who received diatrizoate oral contrast for abdominopelvic CT
Diatrizoate: Administration of diatrizoate oral contrast agent prior to CT scan</description>
        </group>
        <group group_id="E3">
          <title>Iohexol</title>
          <description>Patients who received iohexol oral contrast for abdominopelvic CT
Iohexol: Administration of iohexol oral contrast agent prior to CT scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Benjamin Yeh</name_or_title>
      <organization>UCaliforniaSF</organization>
      <phone>4155149318</phone>
      <email>ben.yeh@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

